异基因骨髓移植的植入证明

CYTOGENETIC STUDIES OF ALLOGENIC BONE MARROW TRANSPLANTATION

本文对我院1987年12月至1989年11月间进行的9例HLA相合的异基因骨髓移植供受者的植入情况做了分析。我们采用了国际骨髓移植登记处的移植成功指标,及常规的细胞遗传学检查,结果全部患者均有间接的临床植入证据,其中5例有直接的细胞遗传学证据。本文综合文献提示,细胞遗传学分析在移植证明中具有很重要的意义,但其缺陷也是显而易见的。DNA-RFLP的检测可弥补常规方法的缺陷,并获得准确可靠的植入依据。

Recently, bone marrow transplantation (BMT) has become an important treatment for malignant blood diseases. The successful engraftment is characterized by the IBMTR's criteria: 1) living more than 21 days after BMT; 2) recovery of haemopoiesis; 3) occurrence of acute/chronic GVHD; 4) Cytogenetic evidence. The more imformative evidence is obtained by cytogenetic studies. From Dec, 1987 to Sept, 1989, patients with acute/chronic leukemia were given marrow graft from their HLA-identical siblings. We used RBC typing, blood cell isozymes, chromosomes markers as genetic markers to document the degree of engraftment. 5 of 9 patients had direct cytogenetic evidence, 2 had different RBG typing, 3 had different chromosomes changes. The other 4 had indirect clinical evidence. We conclude that the cytogenetic markers are valuable in the study of engraftment after allo-BMT. The more informative evidence should be DNA-RFLP analysis.